The clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease needs to be combined with a comprehensive assessment of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumor diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to the changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL-PET positive. The platform serves a team of internationally authoritative experts in the field of blood tumours at home and abroad in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.